Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Genmab Ord Shs GNMSF

Healthcare Biotechnology
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA... see more

Recent & Breaking News (OTCPK:GNMSF)

Genmab Announces Phase III Study of Daratumumab in Combination with Carfilzomib in Multiple Myeloma

GlobeNewswire November 10, 2016

Genmab Announces Financial Results for the First Nine Months of 2016 and Improves 2016 Financial Guidance

GlobeNewswire November 2, 2016

U.S. FDA Grants Priority Review for Daratumumab in Relapsed Multiple Myeloma

GlobeNewswire October 7, 2016

Major Shareholder Announcement

GlobeNewswire September 28, 2016

Major Shareholder Announcement

GlobeNewswire September 22, 2016

Major Shareholder Announcement

GlobeNewswire September 12, 2016

Genmab's Total Number of Voting Rights and Total Share Capital

GlobeNewswire August 31, 2016

Genmab Announces U.S. FDA Approval of Arzerra(r) (ofatumumab) in Combination with Fludarabine and Cyclophosphamide for Relapsed CLL

GlobeNewswire August 31, 2016

Genmab Announces European Regulatory Submission for Daratumumab in Relapsed Multiple Myeloma

GlobeNewswire August 23, 2016

Genmab Announces Submission of Supplemental Biologics License Application to FDA for Daratumumab in Relapsed Multiple Myeloma

GlobeNewswire August 17, 2016

Genmab Enters Commercial License Agreement with Gilead for DuoBody(R) Technology

GlobeNewswire August 10, 2016

Genmab Announces Financial Results for the First Half of 2016 and Improves 2016 Financial Guidance

GlobeNewswire August 9, 2016

Daratumumab Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration in Combination with Standard of Care Regimens for Previously Treated Multiple Myeloma

GlobeNewswire July 25, 2016

Genmab Provides Update on Marketing Authorization Application for Arzerra(r) (ofatumumab) as Maintenance Therapy for Patients with Relapsed CLL

GlobeNewswire June 23, 2016

Genmab Announces Phase III Studies of Ofatumumab in Relapsing Multiple Sclerosis

GlobeNewswire June 2, 2016

Genmab Achieves USD 30 Million Milestone in DARZALEX(r) (daratumumab) Collaboration with Janssen

GlobeNewswire May 30, 2016

Genmab Announces European Conditional Marketing Authorization for DARZALEX(r) (daratumumab) for Multiple Myeloma

GlobeNewswire May 23, 2016

Genmab Announces Positive Topline Result in Phase III POLLUX Study of Daratumumab in Relapsed or Refractory Multiple Myeloma

GlobeNewswire May 18, 2016

Ofatumumab in Combination with Fludarabine and Cyclophosphamide for Relapsed CLL accepted for priority review by FDA

GlobeNewswire May 17, 2016

Genmab Announces Financial Results for the First Quarter of 2016

GlobeNewswire May 10, 2016